Ainos (NASDAQ:AIMD) Stock Rating Lowered by Wall Street Zen

Ainos (NASDAQ:AIMD) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Ainos Stock Performance

Shares of NASDAQ AIMD opened at $3.46 on Friday. The firm has a market capitalization of $16.12 million, a price-to-earnings ratio of -0.69 and a beta of 2.20. Ainos has a one year low of $2.00 and a one year high of $5.00. The business has a fifty day simple moving average of $2.85 and a 200 day simple moving average of $2.83. The company has a current ratio of 2.88, a quick ratio of 1.91 and a debt-to-equity ratio of 0.96.

Ainos (NASDAQ:AIMD) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.99) earnings per share (EPS) for the quarter.

About Ainos

Ainos, Inc, a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan.